How Papa was paid
$5.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Joseph PapaPresident, Chief Executive Officer and Director | $1,037,385 | $1,638,500 | $1,191,500 | $1,446,640 | $7,122 | $5,321,147 |
| Richard LindahlExecutive Vice President, Chief Financial Officer | $662,020 | $851,950 | $753,053 | $431,200 | $10,500 | $2,708,723 |
| Coleen GlessnerExecutive Vice President, Quality and Ethics and Compliance | $623,551 | $362,500 | $263,606 | $406,082 | $8,519 | $1,664,258 |
| Simon LowryChief Medical Officer and Head of Research and Development | $545,002 | $362,500 | $263,606 | $289,668 | $10,500 | $1,471,276 |
| Paul WilliamsSenior Vice President, Products Business | $495,019 | $362,500 | $263,606 | $262,608 | $7,425 | $1,391,158 |
What changed and why
- $5.9MCEO total compensation decreased from $5,862,562 in 2024 to $5,321,147 in 2025.
- 107%Annual cash incentive payouts were approved at 107% based on corporate performance factors.
- 25%The 2023-2025 performance stock units were paid out at 25% following the exercise of upward committee discretion.
- $742.9MTotal revenue was $742.9 million compared to $1,043.6 million in 2024.
- $52.6MNet income reached $52.6 million compared to a net loss of $(190.6) million in 2024.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.